#1Pending#2Disclaimer The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc ("Imricor") and its activities. The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars. This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition. We use words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward- looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management's expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled 'Risk factors' in Imricor's prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction. ersonal use only 2 Imricor FY20 Investor Presentation, February 2021#3Pending#4Pending#5ersonal use only 5 Key achievements in 2020 CE mark approval received enabling the sale of Imricor's products in the European Union Successful commercial launch at Heart Centre Dresden also providing training to future sites 9 sites contracted¹ with a growing pipeline of new sites Sales agreement with Philips enabling Philips to sell Imricor's capital equipment as part of iCMR lab installation package ווי - Strategic agreements signed that further promote future iCMR lab adoption Solid progress on growth strategies remaining on track with initiatives to expand indications and geographies 1. As at 30 December 2020 Imricor FY20 Investor Presentation, February 2021#6ersonal use only Lab roll out update TEMP ABL. CATH CATH imricor 回! MR 1157 n 100 G ADVANTAGE-MR Digital Amplifier Stimulator ABL CATH CATH 2 imricor Imricor FY20 Investor Presentation, February 2021#7Pending#8Pending#9ersonal use only 6 Future acceleration in lab rollout plans underpinned by strong pipeline 9 sites with agreements to purchase Imricor's Nine clinical sites now contracted across Germany, The Netherlands & France • Dresden Heart Centre, Germany, a training Centre of Excellence; . Haga Hospital, The Netherlands; • . • Amsterdam University Medical Centre, The Netherlands; Leipzig Heart Centre, Germany, a training Centre of Excellence; Rhön Clinic Bad Neustadt Campus, Germany; Maastricht University Medical Centre, The Netherlands; products • South Paris Cardiovascular Institute, France; and . Lübeck University Heart Centre, UKSH, Germany. • Münster University Hospital, Germany Initial sites (e.g. Dresden, Leipzig) are set up as training Centres of Excellence for sites that follow • • Strong pipeline • • • Discussions well advanced across a number of sites, many at final stage of review and execution Strong and growing pipeline of potential sites supported by increasing awareness and education of Imricor's product Agreement with Sana GPO provides access to ~80 sites for sales & marketing Further enhanced by Philips sales distribution agreement and collaborative relationship with Siemens to drive lab adoption. A well-developed longer-term pipeline aligned with capital cycles of clinical sites Expecting to recommence signing new agreements during the second quarter, accelerating in the second half of 2021 Imricor FY20 Investor Presentation, February 2021#10Pending#11ersonal use only 11 Maintaining a strong focus on growth drivers through COVID Despite the COVID-19 pandemic stalling lab roll out plans during 2020, Imricor maintained clear focus on progressing initiatives across the business to support future growth ✓ Launched online training and education seminars ✓ Contracted nine sites and significantly grew the pipeline of potential new sites ✓ Signed a sales agreement with Philips to sell Imricor's capital equipment as part of Phillips iCMR implementation package & working towards a similar agreement with Siemens Signed a master purchasing agreement with Sana GPO, streamlining access to -80 sites performing cardiac ablations ✓ Awarded a contract from the US National Institutes of Health (NIH) to develop an MRI compatible myocardial biopsy system ✓ Entered into agreements with Optoacoustics & Osypka to provide a sales channel for the supply of products to Imricor's customers for iCMR ablation procedures ✓ Progressed strategy around regulatory approvals to expand indications and geographic reach ✓ Continued to expand the workforce to ensure capacity and capability to deliver Imricor's growth strategy Imricor FY20 Investor Presentation, February 2021#12ersonal use only Partnering to drive growth in clinical sites Imricor entered into a number of agreements in 2020 that promote future iCMR lab adoption • • PHILIPS Sana A worldwide leading manufacturer of MRI equipment Non-exclusive collaborative sales distribution agreement Enables the sale of Imricor's capital product, Advantage-MR EP Recorder/Stimulator System as part of Philips comprehensive iCMR lab installation package¹ Enables the extensive Philips sales force to drive iCMR lab adoption Imricor continues to be the exclusive provider of its consumable devices • Einkauf & Logistik Largest Group Purchasing Organisation in Germany, with 600 cooperating hospitals and medical institutions across Germany & Switzerland Imricor products included in approved catalogue, establishing pricing and eliminating time consuming contract negotiations Streamlines access to ~80 sites that perform cardiac ablations for sales and marketing activities . . . Opto acoustics Leading provider of innovative optical communication solutions for MRI applications Facilitates the introduction of the IMROCTM Wireless Multichannel Communication System to Imricor customers Innovative noise cancelling communication technology supporting iCMR adoption Establishes an important sales channel ensuring availability as new sites are launched Referral fee-based agreement • OSYPKA Technology for an active life Leading German producer of radiofrequency ablation generators Under the agreement Imricor will sell Osypka's HAT 500 radiofrequency ablation generator system to customers for use in iCMR ablation procedures The HAT 500 is compatible with Imricor's Advantage-MR EP Recorder/Stimulator, replacing the discontinued Abbott IBI T11 ablation generator. 12 1. In European countries that recognise the CE mark Imricor FY20 Investor Presentation, February 2021#13Pending#14Pending#15Pending#16ersonal use only 16 Market opportunity TEMP ABL. CATH CATH imricor 回! MR 1157 n 100 G ADVANTAGE-MR Digital Amplifier Stimulator ABL CATH CATH 2 imricor Imricor FY20 Investor Presentation, February 2021#17ersonal use only 17 A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers Drivers of Global Catheter Ablation Market • Increased incidence of cardiac disease $7,000 $6,000 EU and US Cardiac Ablation Market Catheter Sales (USD M) $5,000 8.3% CAGR $4,000 Shift towards minimally $3,000 invasive procedures Cost effectiveness of catheter ablation as treatment option $2,000 $1,000 $0 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 ■US EU-UK, DE, FR, ES, IT Sources: Millennium Research Group Electrophysiology Mapping and Ablation Devices Europe 2021 July 2020 Millennium Research Group Electrophysiology Mapping and Ablation Devices US 2021 June 2020 Imricor FY20 Investor Presentation, February 2021#18Pending#19Pending#20Pending#21Pending#22ersonal use only 22 22 Driving growth through expanding indications Priority target is Ventricular Tachycardia (VT) driven by growing procedure rates and high value of iCMR for VT 1 Ventricular Tachycardia aorta • Ablation in the left and right ventricles superior vena cava pulmonary artery • Often uses transseptal puncture kit (in Imricor product pipeline) • · • . Requires tracking and mapping system (from MRI manufacturer) Requires defibrillation in MRI (3rd party device in development) Requires 12-lead ECG in MRI (3rd party device in development) All required devices on track for use in VT clinical trial 2 Atrial Fibrillation pulmonary vein right atrium- pulmonary valve tricuspid valve inferior vena cava . Ablation in the left atrium • · • Requires transseptal puncture kit (in Imricor product pipeline) Requires tracking and mapping system (from MRI manufacturer) Benefits from defibrillation and 12-lead ECG in MRI pulmonary vein left atrium mitral valve aortic valve right ventricle -left ventricle Imricor FY20 Investor Presentation, February 2021#23Pending#24Pending#25ersonal use only 25 Financial Performance TEMP ABL. CATH CATH imricor 回! MR 1157 n 100 G ADVANTAGE-MR Digital Amplifier Stimulator ABL CATH CATH 2 imricor Imricor FY20 Investor Presentation, February 2021#26Pending#27ersonal use only Cashflow US$'000 FY19 FY20 Net loss (13,294) (12,446) Convertible note related expenses Other non-cash adjustments 6,684 548 1,548 • Change in other assets and liabilities (566) (1,333) Operating cash flows (6,628) (12,231) Investing cash flows (529) Proceeds from issuance of common stock (net) 7,222 (774) 33,407 Proceeds from convertible notes Proceeds from financing obligation Other financing activities Financing cash flows 1,746 1 1,700 (217) (382) 10,451 33,025 Net change in cash 3,294 20,020 Effect of foreign currency changes on cash Cash at 31 December 166 71 5,049 25,140 27 27 Commentary • • Other non-cash adjustments are primarily related to deprecation and stock-related compensation expense Net operating cash outflows increased $5.6 million on the prior comparative period due primarily to additional staffing, D&O insurance, public company costs and building inventory Investing cash outflows consisted of purchases of manufacturing and R&D equipment and payments for security deposits. During 2020, investing cash outflows also includes leasehold improvements and furniture related to the build out of additional R&D space 2019 Proceeds from issuance of common stock includes $7.0 million related to the Company's IPO and $0.2 related to the exercise of options and warrants 2019 Proceeds from financing obligation relates to the sale- leaseback of the Company's MRI scanner 2020 Proceeds from issuance of common stock includes $12.6 million related to the Company's February placement, $19.2 million related to the Company's November placement, $1.1 million related to the Company's December Security Purchase Plan and $0.5 related to the exercise of options and warrants Imricor FY20 Investor Presentation, February 2021#28Pending#29ersonal use only 29 29 Initiatives to support future growth and drive financial performance • • • • • • Support margin improvements Support the continued increase in manufacturing yields and reduced cycle times Support development and process improvements for ablation catheter, new diagnostic catheter and cables Reduce sterilisation cycle costs by 75% Implement processes for volume growth Implemented robust inventory management system Human resources Support recruiting efforts across all departments Manage onboarding of new employees, ensuring compliance with legal requirements across several countries . Automation of employee benefit platforms to reduce internal resource need Imricor FY20 Investor Presentation, February 2021#30ersonal use only 30 30 Outlook TEMP ABL. CATH CATH imricor 回! MR 1157 n 100 G ADVANTAGE-MR Digital Amplifier Stimulator ABL CATH CATH 2 imricor Imricor FY20 Investor Presentation, February 2021#31Pending#32Pending#33Pending#34Pending#35Pending#36Pending#37Pending#38Pending#39Pending#40Pending#41Pending